BioCentury | Feb 19, 2021
Product Development

Korea Spotlight: Eutilex readying first U.S. trial as cancer company aims for global stage

...By Jeff CraNmer, Executive Editor The first in a series of profiles of South Korean biotechs.Eutilex...
...Heui Choe told BioCentury.The trial, which will be the first run in the U.S. by Eutilex Co. Ltd....
...B. The Chinese company is Eutilex’s second-largest shareholder after Kwon. In addition to its antibody platform, Eutilex...
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

...Date Raised Post-$ 12/31 mcap %chg Bifido Co. Ltd. (KOSDAQ:238200) 12/26/18 $6.6 $65.5 $107.8 65% Eutilex Co. Ltd....
BioCentury | Dec 21, 2018
Product R&D

Cell therapies seek solid ground

...cancer; melanoma; NSCLC Ph I Tumor necrosis factor receptor superfamily member 9 (4-1BB; TNFRSF9; CD137) Eutilex Co. Ltd....
BioCentury | Nov 10, 2017
Company News

Huahai gets license to Eutilex's EU-101

...and commercialize preclinical cancer candidate EU-101 in Taiwan and China, including Hong Kong and Macau. Eutilex...
...for up to $35 million in milestones, plus royalties. Huahai is eligible for royalties if Eutilex...
...Eutilex Co. Ltd., Seoul, South Korea Zhejiang Huahai Pharmaceutical Co. Ltd. (Shanghai:600521), Zhejiang, China Business: Cancer Elizabeth S. Eaton EU-101 Eutilex Co. Ltd. Zhejiang...
BioCentury | Nov 6, 2017
Company News

Huahai gets license to Eutilex's EU-101

...and commercialize preclinical cancer candidate EU-101 in Taiwan and China, including Hong Kong and Macau. Eutilex...
...for up to $35 million in milestones, plus royalties. Huahai is eligible for royalties if Eutilex...
...human mAb targeting tumor necrosis factor (TNF) receptor superfamily member 9 (4-1BB; TNFRSF9; CD137). Elizabeth S. Eaton EU-101 Eutilex Co. Ltd. Zhejiang...
BioCentury | Dec 9, 2016
Financial News

T cell play Eutilex raises W21B in series A

...Immuno-oncology company Eutilex Co. Ltd. (Seoul, South Korea) raised W21 billion ($18.9 million) in a series A round...
...A round from DS Asset Management, Kolon Investment, G.N. Tech Venture and SNU Bio Angel. Eutilex...
...CD137). The company declined to disclose what indications will be evaluated in the trial. Eutilex...
BioCentury | Dec 9, 2016
Financial News

Eutilex completes venture financing

...Management, Kolon Investment, G.N. Tech Venture and SNU Bio Angel. Eutilex Co. Ltd. , Seoul, South Korea Alex Himes Eutilex Co. Ltd....
Items per page:
1 - 7 of 7
BioCentury | Feb 19, 2021
Product Development

Korea Spotlight: Eutilex readying first U.S. trial as cancer company aims for global stage

...By Jeff CraNmer, Executive Editor The first in a series of profiles of South Korean biotechs.Eutilex...
...Heui Choe told BioCentury.The trial, which will be the first run in the U.S. by Eutilex Co. Ltd....
...B. The Chinese company is Eutilex’s second-largest shareholder after Kwon. In addition to its antibody platform, Eutilex...
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

...Date Raised Post-$ 12/31 mcap %chg Bifido Co. Ltd. (KOSDAQ:238200) 12/26/18 $6.6 $65.5 $107.8 65% Eutilex Co. Ltd....
BioCentury | Dec 21, 2018
Product R&D

Cell therapies seek solid ground

...cancer; melanoma; NSCLC Ph I Tumor necrosis factor receptor superfamily member 9 (4-1BB; TNFRSF9; CD137) Eutilex Co. Ltd....
BioCentury | Nov 10, 2017
Company News

Huahai gets license to Eutilex's EU-101

...and commercialize preclinical cancer candidate EU-101 in Taiwan and China, including Hong Kong and Macau. Eutilex...
...for up to $35 million in milestones, plus royalties. Huahai is eligible for royalties if Eutilex...
...Eutilex Co. Ltd., Seoul, South Korea Zhejiang Huahai Pharmaceutical Co. Ltd. (Shanghai:600521), Zhejiang, China Business: Cancer Elizabeth S. Eaton EU-101 Eutilex Co. Ltd. Zhejiang...
BioCentury | Nov 6, 2017
Company News

Huahai gets license to Eutilex's EU-101

...and commercialize preclinical cancer candidate EU-101 in Taiwan and China, including Hong Kong and Macau. Eutilex...
...for up to $35 million in milestones, plus royalties. Huahai is eligible for royalties if Eutilex...
...human mAb targeting tumor necrosis factor (TNF) receptor superfamily member 9 (4-1BB; TNFRSF9; CD137). Elizabeth S. Eaton EU-101 Eutilex Co. Ltd. Zhejiang...
BioCentury | Dec 9, 2016
Financial News

T cell play Eutilex raises W21B in series A

...Immuno-oncology company Eutilex Co. Ltd. (Seoul, South Korea) raised W21 billion ($18.9 million) in a series A round...
...A round from DS Asset Management, Kolon Investment, G.N. Tech Venture and SNU Bio Angel. Eutilex...
...CD137). The company declined to disclose what indications will be evaluated in the trial. Eutilex...
BioCentury | Dec 9, 2016
Financial News

Eutilex completes venture financing

...Management, Kolon Investment, G.N. Tech Venture and SNU Bio Angel. Eutilex Co. Ltd. , Seoul, South Korea Alex Himes Eutilex Co. Ltd....
Items per page:
1 - 7 of 7